CJC-1295 stimulates growth-hormone release and can raise IGF-1. It is claimed to improve sleep, recovery, muscle gain and fat loss.
What CJC-1295 and modified GRF does and why that matters
CJC-1295 copies a hormone signal that tells the pituitary gland to release growth hormone, which can raise IGF-1. The DAC version is designed to stay in the body longer; modified GRF(1-29), often called CJC-1295 without DAC, is a different molecule. CJC-1295 is claimed to support muscle gain, fat loss, sleep and recovery, but short human studies measured hormone levels rather than those practical benefits. [1,2,3,4]
Function evidence: Human hormone response; claimed body and sleep outcomes unproven
What people hope to notice
People are usually interested in CJC-1295 because they hope to sleep more deeply, recover faster after training, gain muscle or lose body fat. The human studies cited here do show that the long-acting DAC molecule can raise growth hormone and IGF-1. They did not test whether participants slept better, became stronger, healed injuries faster or changed their body composition in a useful way. A higher hormone level is a biological effect, but it is not the same as a health or performance benefit. [1,2,3,4]
What supports this description: Short human hormone studies; practical wellness outcomes not tested
CJC-1295 and modified GRF Dosing status
Dose: No established therapeutic dose for the uses discussed here | Frequency: No validated schedule for muscle gain, recovery or aging | Cycle: No evidence-based cycling schedule established | Route: Human CJC-1295 studies used subcutaneous administration
Preparation: No FDA-approved preparation instructions.
The cited studies do not validate internet dosing schedules, mixing with ipamorelin, or a universal shelf life after mixing. Study doses for one molecule cannot be transferred to another. [1,2,3,4]
CJC-1295 and modified GRF Effects
GH and IGF-1 measurements. The long-acting molecule increased GH and IGF-1 in short studies of healthy adults. Hormone changes alone do not demonstrate a clinical benefit. [1]
GH pulsatility. A small study found that pulsatile GH secretion persisted during exposure to long-acting CJC-1295. This does not establish that one formulation is safer than another. [2]
CJC-1295 and modified GRF Side Effects
Limited clinical safety data. FDA identifies serious events associated with CJC-1295, including increased heart rate and systemic vasodilatory reactions, and concerns about immunogenicity and peptide impurities. Reliable risk frequencies for no-DAC products are not established by the cited trials. [3]
Frequently Asked Questions About CJC-1295 and modified GRF
What does DAC mean?
Drug affinity complex describes the albumin-binding modification used to prolong the action of CJC-1295. Modified GRF products sold as no-DAC have a different identity. [1,4]
Is a CJC-1295/ipamorelin stack clinically established?
The studies cited here do not establish that combination's safety or effectiveness for body composition, recovery or sleep. They also do not test compatibility in the same syringe. [1,2]
Is flushing always harmless?
A reaction cannot be classified as harmless from its timing alone. FDA identifies increased heart rate and systemic vasodilatory reactions among serious events associated with CJC-1295. [3]
Evidence
Early human hormone studies; formulation matters. The cited human trials studied long-acting CJC-1295 with albumin binding. They measured GH and IGF-1, not established improvements in athletic recovery or aging. Their results do not validate modified GRF or an ipamorelin combination. [1,2]
Approval status: No FDA-approved CJC-1295 product
References
Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 2006. PMID 16352683
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab, 2006. PMID 17018654
U.S. Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks FDA, 2026. Source
U.S. Food and Drug Administration December 4, 2024 Pharmacy Compounding Advisory Committee waiver: CJC-1295 substance descriptions, page 3 FDA PCAC, 2024. Source
Storage
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
